

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/629933		
		Filing Date	July 29, 2003		
		First Named Inventor	Diana Clarke		
		Art Unit	1645		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	4	Attorney Docket Number	ESCL-P01-124


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LB	AA	6,326,201-B1	12-04-2001	Fung et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
LB	AB	WO 95/18856-A1	07-13-1995	Harvard College		
	AC	WO 96/17924-A2	06-13-1996	Johns Hopkins University		
	AD	WO 00/47720-A2	08-17-2000	Ontogeny, Inc.		
	AE	WO 02/12452-A2	02-14-2002	Curis, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
LB	AF	Abraham, E.J. et al. Insulinotropic Hormone Glucagon-Like Peptide-1 Differentiation of Human Pancreatic Islet-Derived Progenitor Cells into Insulin-Producing Cells. Endocrinol 143(8), 3152-3161 (2002).			
	AG	Ahlgren, U. et al. The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1-deficient mice. Development 122, 1409-1416 (1996).			
	AH	Apelqvist, A. et al. Sonic hedgehog directs specialized mesoderm differentiation in the intestine and pancreas. Curr. Biol. 7, 801-804 (1997).			
	AI	Aziz, A. and Anderson, G.H. Exendin-4, a GLP-1 Receptor Agonist, Modulates the Effect of Macronutrients on Food Intake by Rats. J. Nutr. 132, 990-995 (2002).			
	AJ	Bonner-Weir, S. et al. A Second Pathway for Regeneration of Adult Exocrine and Endocrine Pancreas. Diabetes 42, 1715-1720 (Dec. 1993).			
	AK	Bosco, D. et al. Homologous but Not Heterologous Contact Increases the Insulin Secretion of Individual Pancreatic B-Cells. Exp. Cell Res. 184, 72-80 (1989).			
	AL	de Kretser, D.M. et al. Inhibins, activins and follistatin in reproduction. Human Reprod. Update 8(6), 529-541 (2002).			
	AM	Dell, G. et al. Regulation of a promoter from the mouse insulin like growth factor II gene by glucocorticoids. FEBS Letters 419, 161-165 (1997).			
	AN	Doyle, M.E. and Egan, J.M. Glucagon-Like Peptide-1. Recent Prog. Horm. Res. 56, 377-399 (2001).			

Examiner Signature	<i>Lance</i>	Date Considered	8/4/06
-----------------------	--------------	--------------------	--------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/629933		
		Filing Date	July 29, 2003		
		First Named Inventor	Diana Clarke		
		Art Unit	1645		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	4	Attorney Docket Number	ESCL-P01-124

✓	AO	Edlund, H. Transcribing Pancreas. Diabetes 47, 1817-1823 (Dec. 1998).	
	AP	Edlund, H. Developmental Biology of the Pancreas. Diabetes 50 (Supp.1), S5-S9 (Feb. 2001).	
	AQ	Egan, J.M. et al. The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes. J. Clin. Endocrinol. Metab. 87(3), 1282-1290 (2002).	
	AR	Elghazi, L. et al. Role for FGR2IIIB-mediated signals in controlling pancreatic endocrine progenitor cell proliferation. PNAS 99(6), 3884-3889 (19 March 2002).	
	AS	Fernandes, A. et al. Differentiation of New Insulin-Producing Cells is Induced by Injury in Adult Pancreatic Islets. Endocrinol. 138(4), 1750-1762 (1997).	
	AT	Finley, M.F.A. et al. Synapse Formation and Establishment of Neuronal Polarity by P19 Embryonic Carcinoma Cells and Embryonic Stem Cells. J. Neurosci. 16(3), 1056-1065 (1 Feb. 1996).	
	AU	Gaddy-Kurten, D. et al. Inhibition Suppresses and Activin Stimulates Osteoblastogenesis and Osteoclastogenesis in Murine Bone Marrow Cultures. Endocrinol. 143(1), 74-83 (2002).	
	AV	Githens, S. and Whelan, J.F. Isolation and Culture of Hamster Pancreatic Ducts. J. Tissue Culture Methods 8(3), 97-102 (1983).	
	AW	Githens, S. et al. Biochemical and Histochemical Characterization of Cultured Rat and Hamster Pancreatic Ducts. Pancreas 2(4), 427-438 (1987).	
	AX	Githens, S. The Pancreatic Duct Cell: Proliferative Capabilities, Specific Characteristics, Metaplasia, Isolation, and Culture. J. Ped. Gastroenterol. Nutr. 7, 486-506 (1988).	
	AY	Kaczorowski, D.J. et al. Glucose-responsive insulin-producing cells from stem cells. Diabetes Metab. Res. Rev. 18, 442-450 (2002).	
	AZ	Korbutt, G.S. et al. Islet Transplantation. Adv. Exp. Med. Biol. 426, 397-410 (1997).	
	BA	Lambillotte, C. et al. Direct Glucocorticoid Inhibition of Insulin Secretion. J. Clin. Invest. 99, 414-423 (1997).	
	BB	Lampeter, E.F. et al. Regeneration of Beta-cells in Response to Islet Inflammation. Exp. Clin. Endocrinol. 103, 74-78 (1995).	
	BC	Lumelsky, N. et al. Differentiation of Embryonic Stem Cells to Insulin-Secreting Structures Similar to Pancreatic Islets. Science 292, 1389-1394 (18 May 2001).	
	BD	Madsen, O.D. et al. Pancreatic development and maturation of the islet B cell Studies of pluripotent islet cultures. Eur. J. Biochem. 242, 435-445 (1996).	
✓	BE	Maldonado, T.S. et al. Ontogeny of Activin B and Follistatin in Developing Embryonic Mouse Pancreas: Implications for Lineage Selection. J. Gastrointest. Surg. 4, 269-275 (2000).	

Examiner Signature		Date Considered	8/7/6
--------------------	--	-----------------	-------




PTO/SB/08a/b (08-03)
 Approved for use through 07/31/2008. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/629933
		Filing Date	July 29, 2003
		First Named Inventor	Diana Clarke
		Art Unit	1645
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	ESCL-P01-124
Sheet	3	of	4

BF	Mather, J.P. et al. Activins, Inhibins, and Follistatins: Further Thoughts on a Growing Family of Regulators. P.S.E.B.M. 215, 209-222 (1997).
BG	Nielsen, J.H. et al. Beta cell proliferation and growth factors. J. Mol. Med. 77, 62-66 (1999).
BH	Offield, M.F. et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 122, 983-995 (1996).
BI	Peck, A.B. et al. Use of In Vitro-Generated, Stem Cell-Derived Islets to Cure Type 1 Diabetes. Ann. N.Y. Acad. Sci. 958, 59-68 (2002).
BJ	Perry, D. Patients' Voices: The Powerful Sound in the Stem Cell Debate. Science 287, 1423 (25 Feb. 2000).
BK	Peters, C.T. et al. A Glucagon-Like Peptide-1 Receptor Agonist and an Antagonist Modify Macronutrient Selection by Rats. J. Nutr. 131, 2164-2170 (2001).
BL	Petrovsky, N. et al. Prospects for the Prevention and Reversal of Type 1 Diabetes Mellitus. Drugs 62, 2617-2635 (2002).
BM	Phillips, D.J. and de Kretser, D.M. Follistatin: A Multifunctional Regulatory Protein. Frontiers Neuroendocrinol. 19, 287-322 (1998).
BN	Rosenberg, L. In Vivo Cell Transformation: Neogenesis of Beta Cells From Pancreatic Ductal Cells. Cell Transplant. 4(4), 371-383 (1995).
BO	Schneyer, A. et al. Follistatin-related protein (FSRP): a new member of the follistatin gene family. Mol. Cell. Endocrinol. 180, 33-38 (2001).
BP	Secchi, A. et al. Pancreas and Islet Transplantation: Current Progresses, Problems and Perspectives. Horm. Metab. Res. 29, 1-8 (1997).
BQ	Sutherland, D.E.R. Pancreas and Islet Cell Transplantation: Now and Then. Transplant. Proc. 28(4), 2131-2133 (Aug. 1996).
BR	Tourel, C. et al. Glucagon-Like Peptide-1 and Exendin-4 Stimulate Beta-Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age. Diabetes 50, 1562-1570 (July 2001).
BS	Tourel, C. et al. Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the Beta-Cell Mass During the Prediabetic Period with Glucagon-Like Peptide-1 or Exendin-4. Diabetes 51, 1443-1452 (May 2002).
BT	Van Nest, G. et al. Effects of Dexamethasone and 5-Bromodeoxyuridine on Protein Synthesis and Secretion during in Vitro Pancreatic Development. Dev. Biol. 98, 295-303 (1983).
BU	Wankell, M. et al. The activin binding proteins follistatin and follistatin-related protein are differentially regulated in vitro and during cutaneous wound repair. J. Endocrinol. 171, 385-395 (2001).
BV	Weir, G.C. and Bonner-Weir, S. Scientific and Political Impediments to Successful Islet Transplantation. Diabetes 46(8), 1247-1256 (Aug. 1997).

Examiner Signature	<i>Donk Papp</i>	Date Considered	8/14/6
--------------------	------------------	-----------------	--------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/629933
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	July 29, 2003
				First Named Inventor	Diana Clarke
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	ESCL-P01-124

	BW	Welt, C. et al. Activins, Inhibins, and Follistatins: From Endocrinology to Signaling. A Paradigm for the New Millennium. Exp. Biol. Med. 227, 724-752 (2002).	
--	----	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	8/4/06
-----------------------	--	--------------------	--------



IFW

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/629933
				Filing Date	July 29, 2003
				First Named Inventor	Diana Clarke
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	ESCL-P01-124

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
lfj	AA	6,448,045 B1	09-10-2002	Levine et al	
	AB	US 2003/0138951 A1	07-24-2003	Yin	
	AC	6,242,666 B1	06-05-2001	Sarvetnick et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>L. Anderson</i>	Date Considered	8/7/06
--------------------	--------------------	-----------------	--------

9453154_1